Johnson & Johnson (NYSE:JNJ) stands out in the healthcare world for a reason. Its massive scale, strong research teams, and deep relationships with hospitals and medical professionals give it an edge that’s tough for competitors to match. The company’s Innovative Medicine branch creates treatments for tough diseases, while its MedTech division provides equipment for surgeries, heart care, and a wide range of other medical procedures. This combination of established businesses and recurring demand makes J&J a familiar name in dividend portfolios, alongside other companies featured in 10 Unstoppable Dividend Stocks to Buy.
Put simply, this combination builds a strong moat around J&J’s business. Developing new medicines isn’t easy; it takes years of work, huge investments, and tough regulatory hurdles. Medical devices come with their own advantages, since doctors and hospitals often stick with what they know, and switching suppliers is costly and requires retraining. All these factors help J&J defend its market share and keep its pricing power intact.
However, even a company like J&J isn’t invincible. Patent protection doesn’t last forever, new and better treatments from rivals are always on the horizon, and staying ahead in medical technology means never stopping the innovation process. To keep growing, J&J must constantly roll out new products to replace those losing their edge.
J&J’s most recent results show these challenges. In the third quarter of 2026, sales climbed 5.9% to $25.4 billion. But adjusted earnings per share dropped by 7.5% to $2.59. The reported earnings per share fell much further, to just $0.09, mainly because of a $5.5 billion pretax charge tied to resolving talc litigation, plus some acquisition and partnership costs. On a brighter note, management raised its full-year sales outlook to $101.2 billion and adjusted EPS guidance to $11.10. That’s a positive sign, but the decline in adjusted earnings shows that sales growth alone isn’t enough.
Find JNJ in 10 No-Brainer Stocks to Buy Now
The Market Is Paying for Tomorrow’s Earnings Today
Johnson & Johnson forward P/E ratio is 21.01, and its trailing P/E is 31.23. The difference between the two shows that investors expect earnings to bounce back after recent charges. But here’s the catch: the forward P/E was just 14.43 back in September 2025 and has now jumped to 21.01. In other words, the stock is pricier now, even though its quarterly earnings haven’t kept up.
With this forward P/E, J&J’s implied earnings yield is about 4.76%. That’s just a way of looking at potential returns, and it isn’t guaranteed cash in your pocket. For comparison, the 10-year U.S. Treasury yield is hovering between 4% and 5% these days, so J&J’s yield doesn’t offer a huge bonus over what you’d get from government bonds.
Of course, it’s not a perfect comparison. J&J has the potential to grow its earnings and dividends over time, while Treasuries pay a fixed amount. But if you’re a shareholder, you need to see that growth to justify the risks that come with lawsuits, patent expirations, and the ups and downs of the stock market. The broader dividend market offers other options, too, as highlighted in our unstoppable dividend stocks coverage, where the balance between income, business strength, and valuation remains just as important.
Paying 21 times forward earnings could be reasonable if J&J keeps rolling out new medicines and devices, and if it can keep boosting its profit margins. But if legal costs stay high or if patent losses start to outweigh new products, that price tag is a lot harder to justify. J&J’s diverse lineup of businesses deserves a premium, but there are limits to how much you should pay for quality.
Also read: 10 Best Bear Market Stocks to Invest In Right Now
A Reliable Payer, With a More Modest Income Proposition
J&J’s dividend is a nice perk, but it shouldn’t be the only reason you own the stock. The company pays an annual dividend of $5.36 per share, which works out to a yield of about 2.1%, with a payout ratio around 60.7%. That leaves some room for the company to invest in research, acquisitions, pay down debt, or raise the dividend in the future. JNJ has a 64-year streak of consecutive dividend growth under its belt.
This payout looks manageable, especially given J&J’s reliable cash flow. And with a long track record of raising its dividend, management clearly values rewarding shareholders. Still, even a growing dividend can’t make up for sluggish earnings growth or a falling stock valuation.
The real question is whether future earnings and dividend hikes will be strong enough to boost the stock’s value, making up for the modest starting yield and the risks that come with owning shares at today’s price.
The Verdict
In short, Johnson & Johnson is a solid healthcare company with a reliable dividend, but its current price means the company has to keep delivering strong results. J&J has the strengths needed for long-term growth, but the big question is whether that growth will be steady enough to make paying 21 times forward earnings a smart move.
READ NEXT: U.S. Bancorp’s Dividend Is Doing Its Job. Can the Stock Do Its Part? and PNC Financial Looks Like a Dividend Deal, but There’s a Catch
This article is originally published at Insider Monkey.
